NCT07369011 (ENLIGHTEN-3) is a Phase 3 clinical trial of Eloralintide in Sleep Apnea, Obstructive, sponsored by Eli Lilly and Company.

Who is sponsoring NCT07369011?

NCT07369011 is sponsored by Eli Lilly and Company.

What drugs are being tested in NCT07369011?

Interventions in NCT07369011: Eloralintide, Placebo.

What condition does NCT07369011 study?

NCT07369011 studies Sleep Apnea, Obstructive, Obesity, Overweight.

Is NCT07369011 still recruiting?

NCT07369011 is currently recruiting now. Last updated 3 June 2026.

Last reviewed 2026-06-03 · How we verify

NCT07369011: ENLIGHTEN-3

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Moderate to Severe Obstructive Sleep Apnea, and Obesity or Overweight

Recruiting now Phase 3 Last updated 3 June 2026

What this trial tests

Phase 3 trial testing Eloralintide in Sleep Apnea, Obstructive in 800 participants. Currently enrolling.

Timeline

10 February 2026

Primary endpoint
1 March 2028

1 April 2028

Quick facts

Lead sponsor	Eli Lilly and Company
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	800
Start date	10 February 2026
Primary completion	1 March 2028
Estimated completion	1 April 2028
Sites	129 locations across United States, Argentina, Australia, Brazil, Canada, China, Germany, India

Drugs / interventions tested

Eloralintide — full drug profile →
Placebo

Conditions studied

Sleep Apnea, Obstructive — all drugs for Sleep Apnea, Obstructive →
Obesity — all drugs for Obesity →
Overweight — all drugs for Overweight →

Sponsor

Eli Lilly and Company — full company profile →

Who can join

18 and older, any sex, with Sleep Apnea, Obstructive or Obesity. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 64
Change from Baseline in Apnea-Hypopnea Index (AHI)
Time frame: Baseline, Week 64

Sponsor's own description

The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who are unable or unwilling to use Positive Airway Pressure (PAP) therapy and study YSA2 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study. Participants will be assigned to the Intervention-Specific Appendix (ISA) that reflects their current PAP usage. Participation in the study will last about 76 weeks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Eloralintide

Trials testing the same drug.

NCT06916091 — A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight · Phase 1 · completed
NCT06916065 — A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity · Phase 1 · completed

Other recruiting trials for Sleep Apnea, Obstructive

Currently open trials in the same condition.

NCT06828835 — The REPOSE (Reach for Equity in Pediatric Sleep Evaluation) Navigation Intervention · NA · recruiting
NCT06915831 — Type 1 Diabetes and Obstructive Sleep Apnea · NA · recruiting
NCT07176767 — The IPAD Cohort Study: Insomnia and Positive Airway Pressure Adherence in Children and Adolescents · recruiting
NCT06573372 — Evaluating the Diagnostic Efficacy of Smartwatch and Smartphone for Sleep Apnea · recruiting
NCT06848647 — Treatment of Sleep Apnea to Improve Metabolic Health · recruiting

Other Eli Lilly and Company trials

Trials by the same sponsor.

NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) · Phase 2 · not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo · Phase 2 · not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants · Phase 1 · completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants · Phase 1 · completed
NCT07030127 — A Study of LY3985863 in Healthy Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07369011 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 3 June 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07369011.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing